礼来(LLY)实验性减肥药试验数据不及预期盘前跌7.69% 竞争对手诺和诺德(NVO)涨8.46%

金吾财讯08-07

金吾财讯 | 礼来(LLY)的实验性减肥药试验数据不及预期，盘前跌7.69%；而竞争对手诺和诺德(NVO)则涨8.46%。据一项后期研究显示，从统计结果来看，礼来实验性口服减肥药orforglipron帮助患者成功减重约 11%，该结果低于市场预期。Kepler Cheuvreux 分析师表示，市场曾预期礼来公司的orforglipron药片将成为 Novo 减肥药的强劲竞争对手，上述结果可能导致投资者重新考虑 GLP-1 肥胖药物市场的竞争前景，这种转变有利于诺和诺德的口服司美格鲁肽。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2557666215?lang=en_US&edition=fundamental","thumbnail":"https://static.szfiu.com/news/20210810/N2I5NmMxMDRhMjE5ZjZkNDA5NWY5Njk1NzgzMjA0MDcxNDc1OTcyMzk=.jpg","is_english":false,"pubTime":"2025-08-07 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557666215","market":"nz","top_or_hot":-1,"title":"礼来(LLY)实验性减肥药试验数据不及预期盘前跌7.69% 竞争对手诺和诺德(NVO)涨8.46%","media":"金吾财讯","content":"<html><body><p>金吾财讯 | <a href=\"https://laohu8.com/S/LLY\">礼来</a>(LLY)的实验性减肥药试验数据不及预期，盘前跌7.69%；而竞争对手<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>(NVO)则涨8.46%。据一项后期研究显示，从统计结果来看，礼来实验性口服减肥药orforglipron帮助患者成功减重约 11%，该结果低于市场预期。Kepler Cheuvreux 分析师表示，市场曾预期礼来公司的orforglipron药片将成为 Novo 减肥药的强劲竞争对手，上述结果可能导致投资者重新考虑 GLP-1 肥胖药物市场的竞争前景，这种转变有利于诺和诺德的口服司美格鲁肽。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来(LLY)实验性减肥药试验数据不及预期盘前跌7.69% 竞争对手诺和诺德(NVO)涨8.46%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来(LLY)实验性减肥药试验数据不及预期盘前跌7.69% 竞争对手诺和诺德(NVO)涨8.46%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086022552\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">金吾财讯 </p>\n<p class=\"h-time\">2025-08-07 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>金吾财讯 | <a href=\"https://laohu8.com/S/LLY\">礼来</a>(LLY)的实验性减肥药试验数据不及预期，盘前跌7.69%；而竞争对手<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>(NVO)则涨8.46%。据一项后期研究显示，从统计结果来看，礼来实验性口服减肥药orforglipron帮助患者成功减重约 11%，该结果低于市场预期。Kepler Cheuvreux 分析师表示，市场曾预期礼来公司的orforglipron药片将成为 Novo 减肥药的强劲竞争对手，上述结果可能导致投资者重新考虑 GLP-1 肥胖药物市场的竞争前景，这种转变有利于诺和诺德的口服司美格鲁肽。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"291241","article_id":"2557666215","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20210810/N2I5NmMxMDRhMjE5ZjZkNDA5NWY5Njk1NzgzMjA0MDcxNDc1OTcyMzk=.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557666215","pubTimestamp":1754571813,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾财讯 | 礼来(LLY)的实验性减肥药试验数据不及预期，盘前跌7.69%；而竞争对手诺和诺德(NVO)则涨8.46%。据一项后期研究显示，从统计结果来看，礼来实验性口服减肥药orforglipron帮助患者成功减重约 11%，该结果低于市场预期。Kepler Cheuvreux 分析师表示，市场曾预期礼来公司的orforglipron药片将成为 Novo 减肥药的强劲竞争对手，上述结果可能导致投资者重新考虑 GLP-1 肥胖药物市场的竞争前景，这种转变有利于诺和诺德的口服司美格鲁肽。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LLY":"礼来","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","NVO":"诺和诺德","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","BK4532":"文艺复兴科技持仓","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU0058720904.USD":"联博国际健康护理基金A"},"translate_title":"Eli Lilly (LLY) experimental weight-loss drug trial data fell 7.69% before the market and rival Novo Nordisk (NVO) rose 8.46%","themeId":"354707914f8b173c27b2fcf83d65ef5b","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"LLY":1},"content_text":"金吾财讯 | 礼来(LLY)的实验性减肥药试验数据不及预期，盘前跌7.69%；而竞争对手诺和诺德(NVO)则涨8.46%。据一项后期研究显示，从统计结果来看，礼来实验性口服减肥药orforglipron帮助患者成功减重约 11%，该结果低于市场预期。Kepler Cheuvreux 分析师表示，市场曾预期礼来公司的orforglipron药片将成为 Novo 减肥药的强劲竞争对手，上述结果可能导致投资者重新考虑 GLP-1 肥胖药物市场的竞争前景，这种转变有利于诺和诺德的口服司美格鲁肽。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557666215","isCrawlerRequest":true}